Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics.

Bilal MalikNathan W BartlettJohn W UphamKristy S NicholJohn Harrington Peter A B Wark

Published in: Respirology (Carlton, Vic.) (2023)

ILC2s from severe allergic and eosinophilic asthma demonstrated an active phenotype typified by increased proliferation, TSLPR, GATA3 and NFATc1 expression and increased IL-5, IL-13 and IL-6 release. Mepolizumab reduced markers of ILC2s activation.

Keyphrases

signaling pathway
poor prognosis
nk cells
chronic obstructive pulmonary disease
allergic rhinitis
transcription factor
early onset
lung function
binding protein
cystic fibrosis
drug induced